CHICAGO, June 18, 2025 /PRNewswire/ -- The Medical Billing Software Market share is projected to be valued at USD 17.92 billion in 2024 and...
ASCO 2025 overall survival data bolster IMNN-001’s potential in advanced ovarian cancer, supported by robust translational results at ESMO Results...
Calgary, Alberta--(Newsfile Corp. - June 17, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company")...
PUNE, India, June 16, 2025 /PRNewswire/ -- The global Occupational Health Market was valued at USD 4,796.38 million in 2023 and...
CHICAGO, June 13, 2025 /PRNewswire/ -- The Global Digital Pathology Market is projected to be valued at USD 1.10 billion in 2024...
Patent portfolio now includes protection for manufacture, methods and compositions Provides AIM with patent protection for manufacturing Ampligen until 2041...
Revenue grew 336.5% to $14.4 million from prior year (excluding ACT Genomics)Raises full year revenue outlook to $80 - $100...
Revenue grew 336.5% to $14.4 million from prior year (excluding ACT Genomics)Raises full year revenue outlook to $80 - $100...
Revenue grew 336.5% to $14.4 million from prior year (excluding ACT Genomics)Raises full year revenue outlook to $80 - $100...
Company expected to resume trading on the NYSE American on Tuesday, June 17, 2025OCALA, Fla., June 12, 2025 (GLOBE NEWSWIRE)...
Company expected to resume trading on the NYSE American on Tuesday, June 17, 2025OCALA, Fla., June 12, 2025 (GLOBE NEWSWIRE)...
Company expected to resume trading on the NYSE American on Tuesday, June 17, 2025OCALA, Fla., June 12, 2025 (GLOBE NEWSWIRE)...
Acquisition will strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech’s next key milestone in...
Acquisition will strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech’s next key milestone in...
BEIJING, June 11, 2025 (GLOBE NEWSWIRE) -- Shineco, Inc. ("Shineco" or the "Company"; NASDAQ: SISI), a provider of innovative diagnostic...
Company to receive $7.0 million up front for its preclinical oncology drug candidate Up to $130.0 million in milestone payments starting...
MIAMI, FL, June 11, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on...
- Second-generation norovirus constructs produce statistically significant increases in GI.1 and GII.4 norovirus blocking antibodies (141% and 94%, respectively) compared...
Study is Intended to Verify Previous Discovery Results Demonstrating Sensitivity of 95% and Specificity of 98%BERKELEY, Calif. and MAINZ, Germany,...
Atopic dermatitis is a chronic disease that disproportionately impacts communities of color Dupixent achieved 75% or greater improvement in overall...